media

a:head bio AG today announced a long-term partnership with the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria for the development of next generation central nervous system (CNS) therapeutics and the award of an Early Stage grant from the Austrian Research Promotion Agency (FFG)

a:head bio AG, an Austrian biotech company focusing on the development of next generation therapeutics for the treatment of brain disorders based on human cerebral organoids has recently been incorporated.